Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 9 January 2007
Vol. 2007, Issue 368, p. tw13
[DOI: 10.1126/stke.3682007tw13]


Bone Biology Inhibiting Osteoclast Formation

Nancy R. Gough

Science's STKE, AAAS, Washington, DC 20005, USA

Hyaluronic acid (hyaluronan, HA) is a component of the extracellular matrix and is also used clinically to treat joint and cartilage diseases such as osteoarthritis. Chang et al. show that high molecular mass HA (HMM-HA), but not low molecular mass HA, inhibited osteoclast differentiation of bone marrow-derived macrophages in response to macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor {kappa}B ligand (RANKL). HMM-HA did not block RANKL-stimulated osteoclastogenesis of RAW264.7 cells, which is independent of M-CSF. Although CD44 is one known receptor for HA, antibodies that block CD44 had no effect on the inhibition of osteoclast formation by HA. However, function-blocking antibodies against Toll-like receptor 4 (TLR4) blocked the inhibitory effect of HA, suggesting that HA was acting through the TLR4. TLR4-transfected cells bound labeled HA based on fluorescence-activated cell sorting analysis, and osteoclastogenesis of cells from mice with a nonfunctional TLR4 were not inhibited by HA. HA decreased signaling pathways activated by M-CSF but did not inhibit those activated by RANKL unless the cells were pretreated with HA for 2 days before RANKL exposure. HA decreased the production of reactive oxygen species stimulated by the receptor tyrosine kinase activated by M-CSF and also inhibited activation of Rac and downstream kinases of the mitogen-activated protein kinase family (p38, ERK, and JNK). HA reduced the abundance of RANK and appeared to mediate this effect by its inhibition of M-CSF signaling, because M-CSF leads to the phosphorylation and activation of two transcription factors for which binding sites exist in the RANK promoter. Thus, M-CSF may stimulate osteoclastogenesis by increasing the responsiveness to RANKL through increased abundance of the receptor RANK, and HA blocks this pathway. In a mouse model for bone erosion, implantation of collagen films containing RANKL in the presence or absence of HA onto mouse skulls showed that HA decreased the RANKL-induced bone loss. These results show a possible mechanism by which HA is clinically useful, expand the role of innate immune receptors to regulation of bone metabolism, and provide a potential connection between bone metabolism and the innate immune system.

E.-J. Chang, H. J. Kim. J. Ha, H. J. Kim, J. Ryu, K.-H. Park, U.-H. Kim, Z. H. Lee, H.-M. Kim, D. E. Fisher, H.-H. Kim, Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J. Cell Sci. 120, 166-176 (2007). [Abstract] [Full Text]

Citation: N. R. Gough, Inhibiting Osteoclast Formation. Sci. STKE 2007, tw13 (2007).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882